{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:34:04Z","timestamp":1755225244643,"version":"3.43.0"},"reference-count":21,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinicians should obtain baseline white blood cell differential among those in whom antithyroid drugs (ATD) will be initiated, as patients may have neutropenia prior to initiation of ATD. We report the case of a 37-year-old male individual who had emigrated from Saudi Arabia and was found to have Graves disease. At diagnosis, the patient was leukopenic and neutropenic. Prior neutrophil counts had ranged from moderate neutropenia to normal. The patient was found to have the Duffy-null phenotype on red blood cell antigen typing, which is characterized by a clinically insignificant lower absolute neutrophil count (ANC) relative to commonly used reference ranges and no known increased risk of infection. Despite his baseline neutropenia, the patient received a standard weight-based dose of methimazole. ATD should not be withheld from patients with the Duffy-null phenotype. These patients have fewer circulating neutrophils without an increased risk of infection.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf157","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:00:28Z","timestamp":1750838428000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Graves Disease With Co-Existing Duffy-Null Phenotype"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9377-9129","authenticated-orcid":false,"given":"Grace M","family":"Ferri","sequence":"first","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center , Boston, MA 02118 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Chua","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center , Boston, MA 02118 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa R","family":"Trovato","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center , Boston, MA 02118 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Campos","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston Medical Center , Boston, MA 02118 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sloan","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Boston Medical Center , Boston, MA 02118 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1236-7980","authenticated-orcid":false,"given":"Shirin","family":"Haddady","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Boston Medical Center , Boston, MA 02118 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"3","key":"2025081304271301900_luaf157-B1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025081304271301900_luaf157-B2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ncomms1265","article-title":"The global distribution of the Duffy blood group","volume":"2","author":"Howes","year":"2011","journal-title":"Nat Commun"},{"issue":"23","key":"2025081304271301900_luaf157-B3","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.2023.7467","article-title":"Development of Duffy Null\u2013specific absolute neutrophil count reference ranges","volume":"329","author":"Merz","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"2025081304271301900_luaf157-B4","doi-asserted-by":"crossref","first-page":"e2432475","DOI":"10.1001\/jamanetworkopen.2024.32475","article-title":"Cancer trial eligibility and therapy modifications for individuals with Duffy null-associated neutrophil count","volume":"7","author":"Hibbs","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025081304271301900_luaf157-B5"},{"issue":"10","key":"2025081304271301900_luaf157-B6","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"2025081304271301900_luaf157-B7","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.165.8.869","article-title":"Population-based drug-induced agranulocytosis","volume":"165","author":"Ib\u00e1\u00f1ez","year":"2005","journal-title":"Arch Intern Med"},{"issue":"9","key":"2025081304271301900_luaf157-B8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2025081304271301900_luaf157-B9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/105072504323150787","article-title":"Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis","volume":"14","author":"Tajiri","year":"2004","journal-title":"Thyroid"},{"issue":"6","key":"2025081304271301900_luaf157-B10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/thy.2008.0364","article-title":"Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30\u2005mg daily than with 15\u2005mg daily","volume":"19","author":"Takata","year":"2009","journal-title":"Thyroid"},{"issue":"7","key":"2025081304271301900_luaf157-B11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1507\/endocrj.EJ24-0135","article-title":"Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil","volume":"71","author":"Yoshimura Noh","year":"2024","journal-title":"Endocr J"},{"issue":"5","key":"2025081304271301900_luaf157-B12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2265.2004.02135.x","article-title":"Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK","volume":"61","author":"Pearce","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025081304271301900_luaf157-B13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1507\/endocrj.EJ12-0332","article-title":"The relationship between bone marrow characteristics and the clinical prognosis of antithyroid drug-induced agranulocytosis","volume":"60","author":"Yang","year":"2013","journal-title":"Endocr J"},{"issue":"3","key":"2025081304271301900_luaf157-B14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.1991.tb08042.x","article-title":"Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes","volume":"79","author":"Juli\u00e1","year":"1991","journal-title":"Br J Haematol"},{"issue":"17","key":"2025081304271301900_luaf157-B15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0755-4982(04)98884-7","article-title":"Prognostic factors of hematological recovery in life-threatening nonchemotherapy drug-induced agranulocytosis: a study of 91 patients from a single center","volume":"33","author":"Maloisel","year":"2004","journal-title":"Presse M\u00e9d"},{"key":"2025081304271301900_luaf157-B16","doi-asserted-by":"crossref","first-page":"1064723","DOI":"10.3389\/fendo.2023.1064723","article-title":"Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Endocrinol"},{"issue":"8","key":"2025081304271301900_luaf157-B17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/qjmed\/92.8.455","article-title":"Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections","volume":"92","author":"Sheng","year":"1999","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"3","key":"2025081304271301900_luaf157-B18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/pds.1542","article-title":"Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis","volume":"17","author":"Ib\u00e1\u00f1ez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2025081304271301900_luaf157-B19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/cen.14313","article-title":"Neutropenia in patients with hyperthyroidism: systematic review and meta-analysis","volume":"94","author":"Scappaticcio","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025081304271301900_luaf157-B20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood-2014-02-482612","article-title":"How we evaluate and treat neutropenia in adults","volume":"124","author":"Gibson","year":"2014","journal-title":"Blood"},{"key":"2025081304271301900_luaf157-B21","doi-asserted-by":"crossref","first-page":"1273358","DOI":"10.3389\/fimmu.2024.1273358","article-title":"Graves' disease and systemic lupus erythematosus: a Mendelian randomization study","volume":"15","author":"Xian","year":"2024","journal-title":"Front Immunol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf157\/63858643\/luaf157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf157\/63858643\/luaf157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:27:19Z","timestamp":1755073639000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf157\/8214410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf157","relation":{},"ISSN":["2755-1520"],"issn-type":[{"type":"electronic","value":"2755-1520"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]},"article-number":"luaf157"}}